Nectin-4 Knockout MCF7 Cell line

• Background:

  Nectin-4 is part of the Nectin family and plays a crucial role in cell adhesion. Nectin-4 contains two immunoglobulin-like C2-type domains and one Ig-like V-type domain. In contrast to other Nectins, which are found extensively in adult tissues, Nectin-4 is abundant during fetal development but declines in adult life. Its expression, however, returns specifically in lung, breast, pancreas and ovarian cancers. It was shown that Nectin-4 can modulate the expression of epithelial–mesenchymal transition-related proteins via the PI3K (phosphoinositide 3-kinase) /AKT (protein B kinase) pathway. In addition, a recent study demonstrated that Nectin-4 is a cancer-specific TIGIT ligand, and its expression is also associated with poor prognostic features, suggesting it could be an efficient target for cancer immunotherapy. In 2019, the FDA approved Enfortumab vedotin-ejfv, which is a Nectin-4-directed antibody drug conjugate (ADC) used in treating metastatic urothelial cancer.

• Description:

  Nectin-4 Knockout MCF7 Cell Line is an MCF7 breast cancer cell line in which human Nectin-4 has been genetically removed using CRISPR/Cas9 genome editing with a lentivirus encoding CRISPR/Cas9 gene and sgRNA (single guide RNA) targeting human Nectin-4.This cell line has been validated by genomic sequencing and flow cytometry.Purchase of this cell line is for research purposes only; commercial use requires a separate license. View thefull terms and conditions.

• UniProt:

  Q96NY8

• Applications:

  Study phenotypes resulting from Nectin-4 knockout.Use as negative control in the development of ADC or other biologics targeting Nectin-4.

• Shipping Conditions:

  -80°C

• Storage Conditions:

  Cells are shipped in dry ice and should immediately be thawed or stored in liquid nitrogen upon receipt. Do not use a -80°C freezer for long term storage. Contact technical support at[email protected]if the cells are not frozen in dry ice upon arrival.

• Notes:

  The CRISPR/CAS9 technology is covered under numerous patents, including U.S. Patent Nos. 8,697,359 and 8,771,945, as well as corresponding foreign patents applications, and patent rights.License DisclosureVisitbpsbioscience.com/licensefor the label license and other key information about this product.Troubleshooting GuideVisitbpsbioscience.com/cell-line-faqfor detailed troubleshooting instructions. For all further questions, please email[email protected].